Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x(L), and Bcl-w in vitro, we find that Bcl-2 is the critical target in vi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mérino, Delphine, Khaw, Seong L., Glaser, Stefan P., Anderson, Daniel J., Belmont, Lisa D., Wong, Chihunt, Yue, Peng, Robati, Mikara, Phipson, Belinda, Fairlie, Walter D., Lee, Erinna F., Campbell, Kirsteen J., Vandenberg, Cassandra J., Cory, Suzanne, Roberts, Andrew W., Ludlam, Mary J. C., Huang, David C. S., Bouillet, Philippe
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382939/
https://ncbi.nlm.nih.gov/pubmed/22538851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-400929
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars